Mendez v. Global Institute Of Stem Cell Therapy And Research, USA

District Court, S.D. California·Decided July 29, 2022·No. 3:20-cv-00915·Unknown

Opinion

CHRISTINA MENDEZ, individually and Case No.: 20cv915-LL-BLM on behalf of all others similarly situated, ORDER DISMISSING COMPLAINT Plaintiff, WITH LEAVE TO AMEND AND v. DENYING MOTION TO DISMISS AS MOOT GLOBAL INSTITUTE OF STEM CELL THERAPY AND RESEARCH, USA, et [ECF Nos. 15, 16] al.,

Defendants. In this putative consumer class action, Plaintiff Christina Mendez alleges federal jurisdiction on the basis of the Class Action Fairness Act of 2005, 28 U.S.C. § 1332(d) (“CAFA”). ECF No. 15. Pending before the Court is Plaintiff’s operative First Amended Complaint (“FAC”), id., and a Motion to Dismiss the FAC filed by Global Institute of Stem Cell Therapy and Research, USA (“Giostar”), Giostar Labs, Inc. (“Giostar Labs”), Anand Srivastava, Deven Patel, Siddharth Bhavsar, and Scott Kirkpatrick (together, “Defendants”), ECF No. 16. For the reasons discussed below, this action is DISMISSED WITHOUT PREJUDICE for failure to sufficiently allege federal subject matter jurisdiction. Defendants’ motion to dismiss is therefore DENIED WITHOUT PREJUDICE as moot. Plaintiff is granted leave to amend her complaint pursuant to 28 U.S.C. § 1653. Plaintiff filed this putative consumer class action complaint on May 15, 2020. ECF No. 1. The operative FAC was filed on July 27, 2020. ECF No. 15. The FAC asserts the following claims: (1) violation of California’s Unfair Competition Law (“UCL”), Cal. Bus. & Prof. Code §§ 17200 et seq.; (2) violation of California’s False Advertising Law (“FAL”), Cal. Bus. & Prof. Code §§ 17500 et seq.; (3) violation of California’s Consumers Legal Remedies Act (“CLRA”), Cal. Civ. Code. §§ 1750 et seq.; (4) breach of express warranty; (5) quasi contract; (6) breach of fiduciary duty; (7) fraudulent concealment; (8) intentional misrepresentation; and (9) negligent misrepresentation. Id. Defendants’ motion to dismiss was filed on August 31, 2020. ECF No. 16. “It is to be presumed that a cause lies outside [of federal courts’] limited jurisdiction, and the burden of establishing the contrary rests upon the party asserting jurisdiction.” Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375, 377 (1994) (citations omitted). Federal courts are constitutionally required to raise issues related to federal subject matter jurisdiction and may do so sua sponte. Arbaugh v. Y&H Corp., 546 U.S. 500, 514 (2006). A federal court must satisfy itself of its jurisdiction over the subject matter before proceeding to the merits of the case. Ruhrgas AG v. Marathon Oil Co., 526 U.S. 574, 577, 583 (1999); Snell v. Cleveland, 316 F.3d 822, 826 (9th Cir. 2002) (“Federal Rule of Civil Procedure 12(h)(3)[] provides that a court may raise the question of subject matter jurisdiction, sua sponte, at any time during the pendency of the action . . . .”) (footnote omitted). “A plaintiff suing in a federal court must show in his pleading, affirmatively and distinctly, the existence of whatever is essential to federal jurisdiction, and, if he does not do so, the court, on having the defect called to its attention or on discovering the same, must dismiss the case, unless the defect be corrected by amendment.” Tosco Corp. v. Cmtys. for a Better Env’t, 236 F.3d 495, 499 (9th Cir. 2001) (citation omitted), abrogated on other grounds by Hertz Corp. v. Friend, 559 U.S. 77, 82-83 (2010). “CAFA vests the federal courts with ‘original’ diversity jurisdiction over class actions [of 100 or more persons] if: (1) the aggregate amount in controversy exceeds $5,000,000, and (2) any class member is a citizen of a state different from any defendant.” Serrano v. 180 Connect, Inc., 478 F.3d 1018, 1020-21 (9th Cir. 2007) (citing 28 U.S.C. § 1332(d)). The enactment of CAFA did not alter the longstanding rule that the proponent of federal jurisdiction bears the burden of establishing that jurisdiction. Abrego v. Dow Chem. Co., 443 F.3d 676, 686 (9th Cir. 2006). A. Amount in Controversy Plaintiff’s prayer for relief is silent as to what amount of damages or restitution she seeks and the FAC otherwise fails to calculate or explain how the $5,000,000 bar will be met in light of the injuries alleged. ECF No. 15 at 40. Plaintiff alleges that that cost of her disputed treatment, $22,500, is representative and typical of the amount charged by Defendants for stem cell therapy and that “the claims of the proposed class members exceed $5,000,000 in the aggregate.” Id. ¶¶ 13, 16. Plaintiff’s allegations of class numerosity state that “upon information and belief,” there are “thousands of patients, dispersed throughout the United States, who received Treatment from Defendants,” and “hundreds or thousands of patients from California, who received Treatment from Defendants.” Id. ¶ 119. Plaintiff’s allegations appear to rest solely on Defendants claim that “they ‘successfully treated’ 4,000 patients between 2011 and 2016.” Id. Plaintiff does not provide any basis for the claim that there are thousands or hundreds of putative class members, either in California or in other states, or that the combined amount in controversy would meet the jurisdictional threshold. Plaintiff’s conclusory allegation that the amount in controversy exceeds $5,000,000 is insufficient, without supporting factual allegations, to establish that the amount in controversy requirements under CAFA has been met. Ibarra v. Manheim Invs., Inc., 775 F.3d 1193, 1197 (9th Cir. 2015) (the proponent of federal jurisdiction “has the burden to put forward evidence showing that the amount in controversy exceeds $5 million, to satisfy the requirements of CAFA, and to persuade the court that the estimate of damages in controversy is a reasonable one.”). A party seeking federal jurisdiction needs only to put forward a “plausible allegation that the amount in controversy exceeds the jurisdictional threshold,” if their allegation is not challenged by the opposing party or questioned by the court. Dart Cherokee Basin Operating Co., LLC v. Owens, 574 U.S. 81, 89 (2014). Furthermore, a party “is permitted to rely on ‘a chain of reasoning that includes assumptions.’” Arias v. Residence Inn, 936 F.3d 920, 925 (9th Cir. 2019) (quoting Ibarra, 775 F.3d at 1199). However, “those assumptions cannot be pulled from thin air but need some reasonable ground underlying them.” Ibarra, 775 F.3d at 1199. Because the Court has reservations about whether the amount in controversy meets the CAFA threshold, Plaintiff must support her allegation with evidence establishing the amount in controversy. Dart Cherokee, 574 U.S. at 89. See also Petkevicius v. NBTY, Inc., No. 3:14-cv-02616- CAB-(RBB), 2017 WL 1113295, at *4 (S.D. Cal. Mar. 24, 2017) (“[S]imply stating that the amount in controversy exceeds $5,000,000, without any spe

Free access — add to your briefcase to read the full text and ask questions with AI

Mendez v. Global Institute Of Stem Cell Therapy And Research, USA, (S.D. Cal. 2022).

Mendez v. Global Institute Of Stem Cell Therapy And Research, USA (Mendez v. Global Institute Of Stem Cell Therapy And Research, USA) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Ruhrgas Ag v. Marathon Oil Co.
526 U.S. 574 (Supreme Court, 1999)
Arbaugh v. Y & H Corp.
546 U.S. 500 (Supreme Court, 2006)
Serrano v. 180 Connect, Inc.
478 F.3d 1018 (Ninth Circuit, 2007)
In Re TFT-LCD (Flat Panel) Antitrust Litigation
781 F. Supp. 2d 955 (N.D. California, 2011)
Lira v. Herrera
427 F.3d 1164 (Ninth Circuit, 2005)
Blanca Argelia Arias v. Residence Inn by Marriott
936 F.3d 920 (Ninth Circuit, 2019)
Tosco Corp. v. Communities for a Better Environment
236 F.3d 495 (Ninth Circuit, 2001)
In re Packaged Seafood Products Antitrust Litigation
242 F. Supp. 3d 1033 (S.D. California, 2017)
Augustine v. Talking Rain Beverage Co.
386 F. Supp. 3d 1317 (S.D. California, 2019)